[Recurrent aphthosis: safety of low dose thalidomide].
OBJECTIVE
Thalidomide is an effective treatment for recurrent aphthosis but its effectiveness at low dose has been rarely assessed.


METHODS
Single-centre non-randomized retrospective open study.


RESULTS
Forty-seven patients were treated with thalidomide for recurrent aphthosis (41 patients) or Behçet disease (six patients). Remission was obtained with a dose of 25 mg daily. Discontinuation of treatment for side effects was not observed in this case series.


CONCLUSIONS
Low dose thalidomide below 50 mg daily is an effective and well tolerated treatment of aphthosis.
Gil
H
H
Service de médecine interne, CHU Jean-Minjoz, 1, boulevard Fleming, 25000 Besançon, France. hgil@chu-besancon.fr
Perrin
S
S
Dupond
J-L
JL
Meaux-Ruault
N
N
Hafsaoui
C
C
Limat
S
S
Magy-Bertrand
N
N
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001528:Behcet Syndrome / Q000188:drug therapy; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012074:Remission Induction; D012189:Retrospective Studies; D013281:Stomatitis, Aphthous / Q000175:diagnosis / Q000188:drug therapy*; D013792:Thalidomide / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D013792:Thalidomide